{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:47:33Z","timestamp":1789040853062,"version":"build-2803163510"},"reference-count":32,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2022.1559","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T08:29:21Z","timestamp":1658824161000},"source":"Crossref","is-referenced-by-count":3,"title":["Renin\u2011angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumab"],"prefix":"10.3892","volume":"17","author":[{"given":"Takeshi","family":"Chiba","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo\u2011shi, Hokkaido 006\u20118585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Ujiie","sequence":"additional","affiliation":[{"name":"Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University Hospital, Shiwa\u2011gun, Iwate 028\u20113694, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Yaegashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Iwate Medical University Hospital, Shiwa\u2011gun, Iwate 028\u20113694, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Umehara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo\u2011shi, Hokkaido 003\u20110804, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo\u2011shi, Hokkaido 003\u20110804, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Otaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo\u2011shi, Hokkaido 006\u20118585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichi","family":"Sako","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmaceutics, Nihon Pharmaceutical University, Kitaadachi\u2011gun, Saitama 362\u20110862, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Nakamaru","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmaceutics, Nihon Pharmaceutical University, Kitaadachi\u2011gun, Saitama 362\u20110862, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoji","family":"Meada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmaceutics, Nihon Pharmaceutical University, Kitaadachi\u2011gun, Saitama 362\u20110862, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Kudo","sequence":"additional","affiliation":[{"name":"Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University Hospital, Shiwa\u2011gun, Iwate 028\u20113694, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Tasaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Asahikawa Medical University Hospital, Asahikawa\u2011shi, Hokkaido 078\u20118510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo\u2011shi, Hokkaido 006\u20118585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"key20220808131853_b1-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijc.1634","article-title":"Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy","volume":"97","author":"Lu","year":"2002","journal-title":"Int J Cancer"},{"key":"key20220808131853_b2-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"43496","DOI":"10.1074\/jbc.M307742200","article-title":"Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity","volume":"278","author":"Lu","year":"2003","journal-title":"J Biol Chem"},{"key":"key20220808131853_b3-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/ATVBAHA.108.179663","article-title":"Vascular endothelial growth factor","volume":"29","author":"Ferrara","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20220808131853_b4-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-019-03855-w","article-title":"Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer","volume":"84","author":"Suzuki","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20220808131853_b5-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2217\/fon-2019-0243","article-title":"Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: Subgroup analysis from RAINBOW study","volume":"15","author":"De Vita","year":"2019","journal-title":"Future Oncol"},{"key":"key20220808131853_b6-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"key20220808131853_b7-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10120-018-0811-4","article-title":"Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: A phase 2, open-label study","volume":"21","author":"Yamaguchi","year":"2018","journal-title":"Gastric Cancer"},{"key":"key20220808131853_b8-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000437253","article-title":"Proteinuria in patients with solid tumors treated with ramucirumab: A systematic review and meta-analysis","volume":"60","author":"Abdel-Rahman","year":"2014","journal-title":"Chemotherapy"},{"key":"key20220808131853_b9-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"51492","DOI":"10.18632\/oncotarget.18190","article-title":"Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"key20220808131853_b10-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69 (Suppl 3)","author":"Gordon","year":"2005","journal-title":"Oncology"},{"issue":"e0116527","key":"key20220808131853_b11-BR-17-3-01559","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116527","article-title":"Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer","volume":"10","author":"Feliu","year":"2015","journal-title":"PLoS One"},{"key":"key20220808131853_b12-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00280-018-3580-1","article-title":"Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab","volume":"81","author":"Nihei","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20220808131853_b13-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"key20220808131853_b14-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1111\/bcp.13403","article-title":"Population pharmacokinetic meta-analysis of ramucirumab in cancer patients","volume":"83","author":"O'Brien","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"key20220808131853_b15-BR-17-3-01559"},{"key":"key20220808131853_b16-BR-17-3-01559","doi-asserted-by":"crossref","first-page":"61677","DOI":"10.1109\/ACCESS.2018.2874767","article-title":"Performance Analysis of Google Colaboratory as a Tool for Accelerating Deep Learning Applications","volume":"6","author":"Carneiro","year":"2018","journal-title":"IEEE Access"},{"key":"key20220808131853_b17-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"key20220808131853_b18-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1084\/jem.20162040","article-title":"Protein kinase D at the Golgi controls NLRP3 inflammasome activation","volume":"214","author":"Zhang","year":"2017","journal-title":"J Exp Med"},{"key":"key20220808131853_b19-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1053\/j.ajkd.2004.09.020","article-title":"Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy","volume":"45","author":"Kanesaki","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"key20220808131853_b20-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"key20220808131853_b21-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1152\/physrev.00055.2006","article-title":"Properties of the glomerular barrier and mechanisms of proteinuria","volume":"88","author":"Haraldsson","year":"2008","journal-title":"Physiol Rev"},{"key":"key20220808131853_b22-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/hr.2015.69","article-title":"Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: A meta-analysis","volume":"38","author":"Thamcharoen","year":"2015","journal-title":"Hypertens Res"},{"key":"key20220808131853_b23-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cardiores.2006.04.013","article-title":"The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells","volume":"71","author":"Batova","year":"2006","journal-title":"Cardiovasc Res"},{"key":"key20220808131853_b24-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1681\/ASN.2011121170","article-title":"eNOS deficiency predisposes podocytes to injury in diabetes","volume":"23","author":"Yuen","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key20220808131853_b25-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1291\/hypres.31.841","article-title":"Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency","volume":"31","author":"Nakamura","year":"2008","journal-title":"Hypertens Res"},{"key":"key20220808131853_b26-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin-angiotensin-aldosterone system and progression of renal disease","volume":"17","author":"R\u00fcster","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key20220808131853_b27-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tem.2009.03.005","article-title":"eNOS, metabolic syndrome and cardiovascular disease","volume":"20","author":"Huang","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"key20220808131853_b28-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/ndt\/17.12.2145","article-title":"Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria","volume":"17","author":"Goumenos","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"key20220808131853_b29-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"F155","DOI":"10.1152\/ajprenal.00438.2013","article-title":"Upregulation of mitochondrial Nox4 mediates TGF-\u03b2-induced apoptosis in cultured mouse podocytes","volume":"306","author":"Das","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"key20220808131853_b30-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/hr.2011.184","article-title":"Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity","volume":"35","author":"Nagasu","year":"2012","journal-title":"Hypertens Res"},{"key":"key20220808131853_b31-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000512365","article-title":"Stronger effect of azilsartan on reduction of proteinuria compared to candesartan in patients with CKD: A randomized crossover trial","volume":"46","author":"Suehiro","year":"2021","journal-title":"Kidney Blood Press Res"},{"key":"key20220808131853_b32-BR-17-3-01559","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1159\/000506946","article-title":"Efficacy and safety of ramucirumab in Asian and non-Asian patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Pooled individual data analysis of two randomized studies","volume":"9","author":"Yen","year":"2020","journal-title":"Liver Cancer"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T10:19:00Z","timestamp":1659953940000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2022.1559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2022.1559","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"article-number":"76"}}